MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 598070 | Name: Etiroxate, (S)-

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Etiroxate, (S)- has a lipid-lowering effect.

Chemical Structure

Etiroxate, (S)-
Etiroxate, (S)-
CAS#35530-07-5

Theoretical Analysis

MedKoo Cat#: 598070

Name: Etiroxate, (S)-

CAS#: 35530-07-5

Chemical Formula: C18H17I4NO4

Exact Mass: 818.7336

Molecular Weight: 818.95

Elemental Analysis: C, 26.40; H, 2.09; I, 61.98; N, 1.71; O, 7.81

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Etiroxate, (S)-;
IUPAC/Chemical Name
ethyl (S)-2-amino-3-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)-2-methylpropanoate
InChi Key
LWZCMKGGFONJPB-SFHVURJKSA-N
InChi Code
InChI=1S/C18H17I4NO4/c1-3-26-17(25)18(2,23)8-9-4-13(21)16(14(22)5-9)27-10-6-11(19)15(24)12(20)7-10/h4-7,24H,3,8,23H2,1-2H3/t18-/m0/s1
SMILES Code
N[C@](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)(C)C(OCC)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 818.95 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Schwartzkopff W, Hoffmann H, Nijssen J, Etzel V. [The effect of etiroxate on serum lipids after myocardial infarction or in angina pectoris]. Med Klin. 1976 Sep 17;71(38):1555-63. German. PubMed PMID: 185504. 2: Weisweiler P, Schwandt P. Effects of etiroxate on low density and high density lipoproteins in hypercholesterolemic patients. Atherosclerosis. 1981 Apr;39(1):45-9. PubMed PMID: 7247989. 3: Cervinková Z, Simek J, Trojovská V. Effect of triiodothyronine or etiroxate on DNA synthesis in intact and regenerating liver. Physiol Bohemoslov. 1984;33(6):501-6. PubMed PMID: 6241723. 4: Schwartzkopff W, Russ E. [Comparative studies of the lipid-lowering activity of etiroxate hydrochloride and dextrothyroxine (author's transl)]. MMW Munch Med Wochenschr. 1975 May 9;117(19):827-30. German. PubMed PMID: 805950. 5: Dobiásová M, Vítek V, Kopecká J. Effect of etiroxate on LCAT activity and on certain energy metabolism enzymes in the rat. Physiol Bohemoslov. 1982;31(4):323-7. PubMed PMID: 6215662. 6: Knüchel F. [Clinical experience with etiroxate hydrochloride in patients with primary hyperlipoproteinemia]. Med Welt. 1977 Jan 28;28(4):186-9. German. PubMed PMID: 320426. 7: Zadák Z, Kalinová M, Sobotka L. [Etiroxate treatment for hyperlipoproteinaemia type IIa and IIb (author's transl)]. Cas Lek Cesk. 1982 May 14;121(19):593-5. Czech. PubMed PMID: 7093991. 8: Beckmann R. [Expeimental studies in animals on a new lipid lowering compound: etiroxate hydrochloride (author's transl)]. Arzneimittelforschung. 1979;29(3):499-508. German. PubMed PMID: 582735. 9: Dobiásová M, Vondra K, Matousek V, Válek J. Rate of LCAT-mediated cholesterol esterification and serum lipids during etiroxate therapy in hyperlipoproteinemia. Atherosclerosis. 1982 Apr;42(2-3):251-61. PubMed PMID: 7073804. 10: Banz H, Gall FP. [Therapy of hyperlipoproteinemia type IIa and IIb with etiroxate-HCl. Dose-response comparison]. Fortschr Med. 1979 Nov 8;97(42):1942-1947. German. PubMed PMID: 520990. 11: Lageder H, Irsigler K. Reduction of serum lipids by means of etiroxate (Liponorm). Atherosclerosis. 1975 Nov-Dec;22(3):473-84. PubMed PMID: 1212278. 12: Vondra K, Válek J, Dobiásová M, Honzák R. [Type II hyperlipoproteinaemia treated with etiroxate (author's transl)]. Cas Lek Cesk. 1979 Oct 12;118(40-41):1251-5. Czech. PubMed PMID: 527004. 13: Cervinková Z, Simek J, Egrtová I. [The effect of repeated administration of triiodothyronine or etiroxate on liver regeneration in rats after partial hepatectomy]. Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl. 1985;28(3-4):291-8. Czech. PubMed PMID: 3879914. 14: Schwartzkopff W, Russ E. [Long-term treatment of hyperlipoproteinaemia, types IIa and IIb, with etiroxate (author's transl)]. Dtsch Med Wochenschr. 1975 Apr 11;100(15):815-21. German. PubMed PMID: 164334. 15: Dobiásová M, Vondra K. Cholesterol turnover and risk factors for the development of coronary heart disease. Czech Med. 1982;5(1):16-28. PubMed PMID: 7075390. 16: Canzler H. [Drug therapy of hypercholesterinemias (author's transl)]. MMW Munch Med Wochenschr. 1980 Mar 28;122(13):464-70. German. PubMed PMID: 6769018. 17: Banz H, Gall FP. [Dose-response comparison with etiroxat HCl in hyperlipoproteinemias types IIa and IIb]. Med Klin. 1980 Jan 4;75(1):35-6. German. PubMed PMID: 7366519.